AstraZeneca says adjusting drug pricing over Trump policies

Investing.com -- AstraZeneca has changed its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy, which aims to reduce drug prices for Americans, a senior company executive said on Monday.

David Fredrickson, AstraZeneca's executive vice president for the oncology business, told investors that the company's pricing approach across all launches has evolved in response to the most-favoured-nation policy.

The most-favoured-nation policy seeks lower drug prices for Americans.

You May Also Be Interested In

• Roche obesity drug shows 15.5% weight loss in diabetes trial
• Alkami board opts to remain independent after strategic review
• Velo3D names two executives to lead technology and operations